Need a Note Card?

Don’t look any further. Imagine Note Cards are correspondence cards and are a fabulous addition to your writing desk at home. These cards are perfect for writing a thank you note after a party, or after someone has sent you a gift.

Every year Penny People Designs works with a charity or organizaiton and creates a unique card where 50% of the proceeds from the sale of a card are donated to the charity. Imagine a Cure for Leukemia has been chosen this year by Penny People Designs to be their charity card for 2009. The Cards are $1.50 each and can be customized.
Imagine A Cure for Leukemia is dedicated to expanding the search for a cure with a greater sense of urgency. We are a not-for-profit organization. We raise funds through local community activities and the generosity of individuals and companies in the area. We fund projects where medical breakthroughs have already been achieved and where additional research is needed to turn them into better treatments for people. For more information please visit www.imagineacureforleukemia.com

Blog Category: 

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap